CT-INTERACTIVE-BROKERS
28.2.2022 16:02:07 CET | Business Wire | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced the launch of Traders’ Insight Radio , a new podcast series featuring interviews with executives, thought leaders and market experts from across the financial services industry discussing topical themes impacting global markets and trading. Listeners familiar with Traders’ Insight , Interactive Brokers’ online resource for market commentary, will recognize in-house IBKR podcast hosts providing important context around the singular viewpoints being examined during the conversations.
Intended for a broad audience including both advanced traders and novice investors, Traders’ Insight Radio explores a wide range of interesting topics for any investor and enhances the suite of offerings already available through IBKR Campus , the company’s best-in-class educational resource. Recent and upcoming podcasts will feature conversations on the impact of artificial intelligence (AI) on markets, opportunities in foreign securities and views on cryptocurrency as the new digital asset class. For retail investors just starting out or advanced traders seeking to expand their knowledge base, IBKR Campus includes courses and content on trading, markets and current events, as well as overviews dedicated to IBKR’s products and trading platforms – and now, notable podcast interviews.
“We continue to focus on providing investors with the educational tools needed to improve their understanding of financial markets and trading,” said Steve Sanders, EVP of Marketing and Product Development at Interactive Brokers. “Traders’ Insight Radio complements the resources already available through IBKR Campus and is a new and entertaining way all investors can easily access and benefit from expertise across the finance industry.”
The series was introduced in January and early episodes include a two-part interview with Thomas Peterffy, Founder and Chairman of Interactive Brokers Group, discussing his early trading days as an options market maker and how he successfully introduced technology to the trading floor. Listeners will benefit from Mr. Peterffy’s perspective on a variety of subjects such as cryptocurrency, monetary policy and the impact of rising rates and inflation on the economy, while hearing anecdotes from his storied career. To listen to Mr. Peterffy’s podcast interviews, please visit:
Part 1: "You Mean You Don't Have to Know Anything to Do This?"
Part 2: "Mr. Sosnick, I Do Find You Increasingly Useless"
The latest episodes of Traders’ Insight Radio are available for free on the Traders’ Insight blog, through Interactive Brokers’ trading platforms including Trader Workstation, Client Portal and IBKR Mobile and popular podcasting services including Apple Podcast, Google Podcast, Podbean and Spotify.
For the full suite of free IBKR Campus resources, please see below and visit ibkr.com/campus .
Traders' Academy : Investors can improve their understanding of the products, tools and markets available through Interactive Brokers’ Trader Workstation, Client Portal, IBKR Mobile and TWS API applications.
IBKR Webinars : Investors can watch, listen and learn about current market topics and IBKR tools through live and recorded webinars.
Traders' Insight : Investors can watch, read or listen to market commentary from more than 70 industry professionals, including the new Traders’ Insight Radio.
IBKR Quant : A blog intended for quantitative professionals with an interest in programming, deep learning, IBKR API, AI, Blockchain and other transformative technologies influencing modern markets.
Student Trading Lab : A free online resource for educators looking to blend finance or computer science classwork with real-world trading experience.
About Interactive Brokers Group, Inc.:
Interactive Brokers Group affiliates provide automated trade execution and custody of securities, commodities and foreign exchange around the clock on over 135 markets in numerous countries and currencies, from a single IBKR Integrated Investment Account to clients worldwide. We service individual investors, hedge funds, proprietary trading groups, financial advisors and introducing brokers. Our four decades of focus on technology and automation has enabled us to equip our clients with a uniquely sophisticated platform to manage their investment portfolios. We strive to provide our clients with advantageous execution prices and trading, risk and portfolio management tools, research facilities and investment products, all at low or no cost, positioning them to achieve superior returns on investments. Barron’s ranked Interactive Brokers #1 with 5 out of 5 stars in its February 26, 2021, Best Online Broker Review.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220223006298/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom